Description: Avisa Diagnostics Inc. operates a clinical-stage medical device company. It is developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company offers clinical proof-of-concept through trials in cystic fibrosis, tuberculosis, and community-acquired pneumonia. It also provides bacterial infections, including COPD, cystic fibrosis (CF), non CF bronchiectasis, community acquired pneumonia, and tuberculosis. It focuses on pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia. Avisa Diagnostics Inc. is based in Vancouver, Canada.
Home Page: www.avisadx.com
1660A Old Pecos Trail
Santa Fe,
NM
87505
United States
Phone:
505 820 1400
Officers
| Name | Title |
|---|---|
| Mr. David S. Joseph | Pres, CEO & Chairman |
| Mr. Matt Culler | Advisor |
| Philip Ross | Pres |
| Dr. Graham Timmins Ph.D. | Chief Science Advisor & Member of Science Advisory Board |
| Dr. Richard K. Murray M.D. | Chief Medical Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.756 |
| Price-to-Sales TTM: | 12.6928 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |